COMPARAÇÃO ENTRE O MÉTODO REEQUILÍBRIO TORACOABDOMINAL E A TÉCNICA DE DRENAGEM AUTÓGENA ASSISTIDA SOBRE OS PARÂMETROS FISIOLÓGICOS E DESCONFORTO RESPIRATÓRIO EM RECÉM-NASCIDOS PRÉ-TERMO:ENSAIO CLÍNICO RANDOMIZADO

Assisted Autogenous Drainage (DAA) and the Thoracoabdominal Rebalancing (RTA) method assist in the synergism of abdominal muscles and breathing, which facilitates bronchial hygiene and improves respiratory mechanics. The aim of this study was to compare the RTA method with the DAA on physiological parameters and respiratory distress in preterm newborns (PTNB). This is a randomized clinical trial in which 30 PTNB participated, allocated in two groups (DAA and RTA group), submitted to a treatment protocol that used DAA or RTA. The variables analyzed were peripheral oxygen saturation (SpO₂), respiratory rate (RR) and heart rate (HR) in addition to respiratory distress (DR) by the Silverman Andersen Bulletin (BSA). Data were collected in 2 moments: before randomization and immediately after the end of the protocol. The HR of PTNBs, immediately after, submitted to AAD decreased significantly in relation to the RTA group (p = 0.040). For the variables SpO₂, RR and BSA score, there was no difference between the experimental groups in any of the evaluated moments. On the other hand, in the intra-group comparison, SpO₂ increased (DAA: p = 0.002; RTA: p = 0.004) and FR decreased (DAA: p = 0.015; RTA: p = 0.017) significantly. Thus, the data show that the RTA and DAA do not differ with respect to the variables analyzed in this study, but are safe and have beneficial results in the SpO₂ and RF of PTNBA Drenagem Autógena Assistida (DAA) e o método Reequilíbrio Toracoabdominal (RTA) auxiliam no sinergismo da musculatura abdominal e da respiração, o que facilita a higiene brônquica e melhora da mecânica respiratória. O objetivo deste trabalho foi comparar o método de RTA com a DAA sobre os parâmetros fisiológicos e desconforto respiratório no recém-nascido pré-termo (RNPT). Trata-se de um ensaio clínico randomizado do qual participaram 30 RNPT, alocados em dois grupos (grupo DAA e RTA), submetidos a um protocolo de tratamento que utilizou a DAA ou o RTA. As variáveis analisadas foram a saturação periférica de oxigênio (SpO₂), frequência respiratória (FR) e cardíaca (FC) além do desconforto respiratório (DR) pelo Boletim de Silverman Andersen (BSA). Os dados foram coletados em 2 momentos: antes da randomização e imediatamente após o término do protocolo. A FC dos RNPT, no momento imediatamente após, submetidos à DAA diminuiu significativamente em relação ao grupo RTA (p=0,040). Para as variáveis SpO₂, FR e escore do BSA, não houve diferença entre os grupos experimentais em nenhum dos momentos avaliados. Por outro lado, na comparação intragrupo, a SpO₂ aumentou (DAA: p=0,002; RTA: p=0,004) e a FR diminuiu (DAA: p=0,015; RTA: p=0,017) significativamente. Desta forma, os dados mostram que o RTA e DAA não diferem entre si no que se refere as variáveis analisadas neste estudo, mas se mostram seguros e apresentam resultados benéficos na SpO₂ e FR dos RNPT

The ethanolic extract of Salvia lachnostachys Benth is not maternotoxic, does not alter reproductive performance, but has teratogenic potential

Abstract Salvia lachnostachys Benth is native to Brazil and has anti-inflammatory, anti-arthritic, cytotoxic, antitumor, and antihyperalgesic activities. The population, including pregnant women, consume this plant to treat pain, inflammation, flu, spasms, insomnia, and depression, mainly. There are no safety reports on the use of this plant during pregnancy. The present study aimed to evaluate the effects of S. lachnostachys ethanolic extract (EESl) on reproductive performance, embryofetal development, and DNA integrity of pregnant female mice. Pregnant females were randomly divided into three experimental groups (n = 10): The Control group was treated with a vehicle, and treatment groups were administered with EESl at 100 and 1000 mg/kg, respectively. Treatment occurred by gavage throughout the gestational period until day 18. Afterward, reproductive performance, embryofetal development, and DNA integrity parameters were evaluated. The results indicated that EESl did not alter any reproductive performance parameters. However, it changed embryofetal outcome through reduced placental weight (EESl 100 mg/kg), decreased fetal weight (EESl 100 and 1000 mg/kg), and increased frequency of small for gestational age fetuses (EESl 1000 mg/kg). In addition, EES1 increased the frequency of external, visceral, and skeletal malformations. Because of the above, it is considered that EESl is not maternotoxic, does not alter reproductive performance, but does alter embryofetal development. Its use in the gestational period is not indicated due to its teratogenic potential